prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |review
  • Chamlers J, MacMahon S, Mancia G. Whitworth, et al. WHO-ISH Hypertension Guidelines Committee, 1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension J>Hypertens 1999; 17:151-185.

  • Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens 2000; 13:3S-10S.

  • Lioyd-Jones DM, Evans JC, Larson MG, O Donnedl CJ, Wilson PWF levy D. Cross-classification of INC VI blood pressure stages and risk groups in the Framingham Heart study. Arch Intern Med 1999; 159:2206-2212.

  • United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.

  • Hansson L. Zanchetti A. Carruthers SG, Dahlof B Elmfeldt D, Julius S. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998:351:1755-1762.